

1 **Severe Acute Respiratory Syndrome Coronavirus-2 seropositivity in South-Central Uganda,**  
2 **during 2019 - 2021.**

3 Charles Ssuuna<sup>a</sup>; Ronald Moses Galiwango<sup>a#</sup>; Edward Nelson Kankaka<sup>a</sup>; Joseph Kagaayi<sup>a,b</sup>;  
4 Anthony Ndyanabo<sup>a</sup>; Godfrey Kigozi<sup>a</sup>; Gertrude Nakigozi<sup>a</sup>; Tom Lutalo<sup>a,c</sup>; Robert Ssekubugu<sup>a</sup>;  
5 John Bosco Wasswa<sup>a</sup>; Anthony Mayinja<sup>a</sup>; Martina Cathy Nakibuuka<sup>a</sup>; Samiri Jamiru<sup>a</sup>; John Baptist  
6 Oketch<sup>a</sup>; Edward Muwanga<sup>d</sup>; Larry William Chang<sup>a,e,f,g</sup>; Mary Kate Grabowski<sup>f</sup>; Maria Wawer<sup>a,f</sup>;  
7 Ronald Gray<sup>a,f</sup>; Mark Anderson<sup>h</sup>; Michael Stec<sup>h</sup>; Gavin Cloherty<sup>h</sup>; Oliver Laeyendecker<sup>g</sup>; Steven  
8 James Reynolds<sup>f,g,i</sup>; Thomas C. Quinn<sup>g,i</sup>; David Serwadda<sup>a,b</sup>

9

10 <sup>a</sup>Rakai Health Sciences Program, Kalisizo, Uganda

11 <sup>b</sup>Makerere University School of Public Health, Kampala, Uganda

12 <sup>c</sup>Uganda Virus Research Institute, Entebbe, Uganda

13 <sup>d</sup>Kyotera District Health Office, Kyotera District local government, Ministry of Health, Uganda.

14 <sup>e</sup>Department of International Health, Johns Hopkins Bloomberg School of Public Health,  
15 Baltimore, MD

16 <sup>f</sup>Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD

17 <sup>g</sup>Division of Infectious Disease, Division of Medicine, Johns Hopkins School of Medicine,  
18 Baltimore, MD

19 <sup>h</sup>Abbott Laboratories, Abbott Diagnostics Division, Abbott Park, Illinois, USA.

20 <sup>i</sup>Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National  
21 Institutes of Health, Bethesda, MD

22

23 **Running title:** SARS-CoV-2 seropositivity in South-central Uganda

24

25 **Corresponding author:** Charles Ssuuna, Rakai Health Sciences Program, P.O. Box 279 Kalisizo-  
26 Uganda. Email: [cssuuna@rhsp.org](mailto:cssuuna@rhsp.org) / [ssuunacharles2015@gmail.com](mailto:ssuunacharles2015@gmail.com)

## 27 **Abstract**

28 Globally, key subpopulations have a high risk of contracting SARS-CoV-2. In Uganda, limited  
29 access to personal protective equipment amidst lack of clarity on the extent of the community  
30 disease burden may exacerbate this situation.

31 We assessed SARS-CoV-2 antibody seroprevalence among high-risk sub-populations, including  
32 healthcare workers, persons within the general population previously reporting experiencing key  
33 COVID-19 like symptoms and archived plasma specimens collected prior to confirmation of  
34 COVID-19 in Uganda.

35 We collected venous blood from HCWs at selected health facilities and from population-cohort  
36 participants who reported specific COVID-19 like symptoms in a prior phone-based survey  
37 conducted during the first national lockdown (May-August 2020). Pre-lockdown plasma collected  
38 from individuals considered high risk for SARS-CoV-2 infection was retrieved. Specimens were  
39 tested for antibodies to SARS-CoV-2 using the CoronaChek™ rapid COVID-19 IgM/IgG lateral  
40 flow test assay. IgM only positive samples were confirmed using a chemiluminescent  
41 microparticle immunoassay (ARCHITECT AdviseDx SARS-CoV-2 IgM) which targets the spike.  
42 SARS-CoV-2 exposure was defined as either confirmed IgM, both IgM and IgG or sole IgG  
43 positivity.

44 The seroprevalence of antibodies to SARS-CoV-2 in HCWs was 21.1% [95%CI: 18.2-24.2]. Of  
45 the phone-based survey participants, 11.9% [95%CI: 8.0-16.8] had antibodies to SARS-CoV-2.  
46 Among 636 pre-lockdown plasma specimens, 1.7% [95%CI: 0.9-3.1] were reactive.

47 Findings suggest a high seroprevalence of antibodies to SARS-CoV-2 among HCWs and  
48 substantial exposure in persons presenting with specific COVID-19 like symptoms in the general  
49 population of South-central Uganda. Based on current limitations in serological test confirmation,  
50 it remains unclear whether pre-lockdown seropositivity implies prior SARS-CoV-2 exposure in  
51 Uganda.

52 **Key words:** SARS-CoV-2 seroprevalence, healthcare workers, COVID-19, South-central Uganda

## 53 INTRODUCTION

54 It is over a year since SARS-CoV-2 emerged[1] as a global pandemic and as of the 2<sup>nd</sup> of  
55 August 2021, nearly two hundred million cases were reported globally with >4,000,000  
56 fatalities[2]. Transmission occurs by respiratory droplets, aerosols, and via fomites and is higher  
57 in confined or congested spaces[3]. SARS-CoV-2 infection can be asymptomatic[4] with estimates  
58 ranging from 5% – 80% while symptoms are largely nonspecific and include features of flu-like  
59 illness[5]. Diagnosis of asymptomatic and mild cases may be missed due to prioritization of  
60 screening/confirmatory tests for individuals with moderate to severe symptoms. However,  
61 asymptomatic and pre-symptomatic persons can be highly contagious and contribute greatly to  
62 epidemic spread[6, 7].

63 As of the 3<sup>rd</sup> of August 2021, more than 94,000 cases with 2,710 deaths were documented  
64 in Uganda[2]. Community transmission is on the rise[8] despite earlier control measures that

65 included a phased nationwide lockdown between March and August 2020[9]. The SARS-CoV-2  
66 diagnostic testing landscape in Uganda prioritizes testing for symptomatic persons. It is unknown  
67 how many infected asymptomatic persons are missed due to this symptom-based testing approach  
68 and what impact this has on community transmission.

69 HCWs in particular are at a higher risk of contracting SARS-CoV-2[10, 11] and  
70 inadvertently transmitting it to their patients, some of whom may be immunocompromised.  
71 According to the World Health Organization (WHO), they account for 10% of the global SARS-  
72 CoV-2 burden[12]. This risk may be higher in countries like Uganda, due to shortage of Personal  
73 Protective Equipment (PPE) amidst unquantified community disease burden. Notably, several  
74 HCWs in Uganda have been infected and a number have died[13].

75 Due to the limited testing capacity, there are likely to be many undetected community  
76 infections fueling the epidemic. It is also unknown if SARS-CoV-2 importation or exposure in  
77 Uganda might have occurred earlier than the first (official) case reported on the 21<sup>st</sup> of March  
78 2020. We aimed at determining the prevalence of antibodies to SARS-CoV-2 among selected high-  
79 risk sub-populations in South-central Uganda, including HCWs, persons who previously reported  
80 specific COVID-19 like symptoms (fever, cough, loss of taste and smell) in the preceding 30 days,  
81 between May and August 2020. Additionally, we aimed at exploring the possibility of prior SARS-  
82 CoV-2 importation/exposure in South-Central Uganda before confirmation of the first (official)  
83 case on the 21<sup>st</sup> of March 2020.

## 84 **METHODS**

85 **Ethical approval:** The study was approved by the Uganda Virus Research Institute's  
86 Research Ethics Committee (Ref. GC/127/20/08/785), registered, and cleared by the Uganda

87 National Council for Science and Technology (UNCST) (registration number HS878ES). Written  
88 informed consent was obtained from participants before blood specimens and other data were  
89 collected. Also, only archived pre-lockdown plasma specimens from Rakai Community Cohort  
90 Study (RCCS) participants that had provided prior consent for use of their blood specimens in  
91 future studies were retrieved to assess prior SARS-CoV-2 exposure in Uganda.

92 **Study design and setting:** This study was cross-sectional and was conducted at the Rakai  
93 Health Sciences Program (RHSP) with participants recruited from within and outside the Rakai  
94 Community Cohort Study (RCCS) in four districts of South-central Uganda (Masaka, Kyotera,  
95 Rakai and Lyantonde). The RCCS is an open, population-based cohort in 40 communities in these  
96 districts with surveys conducted ~ every 18 months among ~ 23,000 adults, resident in fishing,  
97 agrarian, or peri-urban/trading community settings[14].

98 **Study population and sample size:** A total of 980 participants including 753 HCWs  
99 and 227 individuals from the RCCS phone-based survey were recruited into the study. Participants  
100 from the cohort had previously reported experiencing COVID-19 like symptoms (fever, cough,  
101 loss of taste and/or loss of smell) in the preceding 30 days during an earlier phone-based survey  
102 conducted between May and August 2020. HCWs were identified from health facilities in the  
103 region, prioritizing high volume facilities located near the Uganda-Tanzania border or along the  
104 Kampala-Mutukula highway serving mobile persons who may be at higher risk of SARS-CoV-2  
105 acquisition. At the selected health facilities, all available, willing HCWs were recruited into the  
106 study.

107 Additionally, we retrieved 636 archived plasma specimens collected between October 2019 and  
108 March 18<sup>th</sup>, 2020, before the first national lockdown took effect. Selected samples of persons living

109 in RCCS communities close to the Tanzanian border and along the Kampala-Mutukula highway  
110 were considered to have a high risk for SARS-CoV-2 infection due to their high mobility and  
111 interaction with cross-border populations. They included traders/vendors, commercial sex work  
112 clients, fisher folks, bike (boda-boda) riders, truck drivers, mechanics, shopkeepers, and bar  
113 owners/workers.

114 **Sample / Data collection:** Participants in the phone-based survey conducted during the  
115 first lockdown and reported having previously experienced at least one of the above COVID-like  
116 symptoms were contacted for participation in this study. Additionally, study field teams  
117 approached HCWs at selected health facilities for participation. Consenting participants provided  
118 4mls of venous blood specimens while a short questionnaire was administered to HCWs to collect  
119 data on participant demographics, cadre, prior SARS-CoV-2 exposure, and PPE access/use.  
120 Plasma was frozen (-80°C) until laboratory analysis.

121 **Laboratory analysis:** Frozen plasma was thawed and tested for antibodies to SARS-CoV-  
122 2 using the CoronaChek™ rapid COVID-19 IgM/IgG lateral flow test assay as per manufacturer's  
123 instructions. This assay was previously validated with Ugandan samples, including 1077 pre-  
124 pandemic samples from the RCCS[15]. Low specificities of SARS-CoV-2 antibody assays have  
125 been reported, particularly from malaria endemic regions[16, 17]. Therefore, any sample that was  
126 solely IgM positive by CoronaChek™ was retested by the Abbott ARCHITECT AdviseDx SARS-  
127 CoV-2 IgM chemiluminescent microparticle immunoassay (CMIA) (Abbott, Chicago, IL).

128 **Data analysis:** SARS-CoV-2 exposure was defined as either IgM confirmed by the  
129 ARCHITECT CMIA assay, both IgM and IgG or IgG sole positivity. Point prevalence and 95%

130 confidence intervals were determined for each sub-group using the exact Clopper-Pearson method  
131 of calculating confidence intervals for binomial proportions.

## 132 **RESULTS**

133 **Healthcare workers' SARS-CoV-2 antibody test results:** Most of the  
134 participants were female (64.54%) and were 25-34 years of age (31.6%). In the initial screening  
135 using the CoronaChek™, 30.8% (232/753) of HCWs had detectable SARS-CoV-2 antibodies  
136 irrespective of isotype class. Of these, 119 tested positive for IgM only, 102 for both IgM and IgG  
137 and 11 for IgG only. Of the initially 119 IgM only reactive samples, 46 were confirmed positive  
138 when re-tested using the ARCHITECT assay. The overall seroprevalence of SARS-CoV-2  
139 antibodies among HCWs was 21.1% [95%CI: 18.2-24.2] (159/753). Majority (24/26) of the  
140 sampled health facilities had at least one healthcare worker who had antibodies to SARS-CoV-2.  
141 Seropositivity was highest among nurses and lowest among medical officers (**Table 1**).

142 A total of 128 HCWs reported having undergone prior SARS-CoV-2 RT-PCR testing with 16  
143 reporting a positive result. Of the 16 individuals, 8 had detectable antibodies to SARS-CoV-2. Out  
144 of the 128, a total of 108 HCWs reported previous negative RT-PCR results and 27% of these,  
145 subsequently tested antibody positive. Only face masks were reported to have been used by all  
146 HCWs who reported prior contact with a confirmed COVID-19 case. Despite reporting consistent  
147 use of face masks, 40% (63/156) of the HCWs reporting previous contact with a confirmed  
148 COVID-19 case had antibodies to SARS-CoV-2.

149 **Cohort participants' SARS-CoV-2 antibody test results:** Females  
150 comprised 69.1% and most participants were aged 35-44 years. Upon initial screening using the

151 CoronaChek™, 16.3% of the participants (37/227) tested positive on IgM only, 2.2% (5/227)  
152 tested positive on IgG only whereas 6.6% (15/227) were positive on both IgM and IgG. Following  
153 retesting of the initially IgM only reactive samples using the ARCHITECT assay, 7/37 were  
154 confirmed positive. The overall seroprevalence of antibodies to SARS-CoV-2 in this population  
155 was 11.9% [95%CI: 8.0-16.8] (27/227). There was nearly no difference in seropositivity among  
156 HIV positive and negative participants (**Table 2**).

157

158 **Pre-lockdown SARS-CoV-2 antibody test results:** Upon initial screening using  
159 the CoronaChek™, 7% (47/363) of specimens had detectable antibodies to SARS-CoV-2  
160 irrespective of isotype class. The majority (44) were IgM sole reactive, 2 were positive on IgG  
161 only whereas 1 reacted for both IgM and IgG. Out of the 44 IgM sole positive samples, 8 were  
162 confirmed following re-testing using the ARCHITECT assay. The overall seroprevalence of  
163 antibodies to SARS-CoV-2 in this sample category was 1.7% [95%CI: 0.9-3.1] (11/636).

164

## 165 **DISCUSSION**

166 These findings suggest a relatively high SARS-CoV-2 seroprevalence among HCWs at  
167 almost all the selected health facilities (24/26) in South-central Uganda and substantial  
168 seroprevalence in persons previously reporting specific COVID-19 like symptoms within the  
169 general population. There was also potentially a spike in transmission a few weeks prior to this  
170 evaluation with predominance of IgM only antibodies in most of the participants.



171           There are challenges interpreting SARS-CoV-2 rapid serology in regions with high malaria  
172    endemicity as infection with *Plasmodium* species was shown to induce cross-reactive antibodies  
173    to carbohydrate epitopes on the SARS-CoV-2 spike protein[17, 18]. It is thus unclear whether  
174    seropositivity in pre-lockdown plasma specimens implies prior SARS-CoV-2 or other related  
175    coronavirus exposure or malaria in Uganda.

176           HCWs are minimally protected by face masks and only a few had accesses to other PPE  
177    (face shields, gowns, aprons etc.) and this, coupled with likelihood of improper face mask use or  
178    lack of N95-level protection, could explain the positive COVID-19 antibody results observed even  
179    among participants reporting face mask use. Several undetected cases among HCWs in this region  
180    is a potential driver of nosocomial spread. A moderate concordance between reported RT-PCR  
181    COVID-19 positives and antibody test outcome may reflect waning antibody levels as reported in  
182    several publications [19, 20].

183    **Acknowledgements: Source of funding:** This work was funded by the Government of  
184    Uganda through Makerere University Research and Innovations Fund (Grant number  
185    RIF/COVID/075, <https://rif.mak.ac.ug/> ) and in part by the Division of Intramural Research,  
186    National Institute of Allergy, and Infectious Diseases (NIH, <https://www.niaid.nih.gov/about/dir>  
187    ). The funders had no role in study design, data collection and interpretation, or the decision to  
188    submit the work for publication. **Personal assistance: Samples/Data collection:** RCCS  
189    field team, District Health Officers of Rakai, Kyotera, Lyantonde and Masaka districts, Prossy  
190    Namutebi, Wilson Bwanike; **Data management:** Damalie Nansimbi, Muhammed Mugerwa,  
191    Darix Ssebagala Kigozi

192 **Author contributions: Protocol development:** Ronald M. Galiwango, David  
193 Serwadda, Edward N. Kankaka, Charles Ssuuna, Thomas C. Quinn, Kate M. Grabowski, Larry W.  
194 Chang, Steven J. Reynolds, Maria J. Wawer, Ronald H. Gray; **Study implementation:** Charles  
195 Ssuuna, Ronald M. Galiwango, David Serwadda, Robert Ssekubugu, John Bosco Wasswa,  
196 Anthony Ndyababo, Edward Muwanga, Martina Cathy Nakibuuka, Samiri Jamiru, John Baptist  
197 Oketch, Anthony Mayinja Mark Anderson, Michael Stec, Gavin Cloherty; **Manuscript**  
198 **development:** Charles Ssuuna, David Serwadda, Ronald M. Galiwango, Edward Kankaka,  
199 Joseph Kagaayi, Godfrey Kigozi, Gertrude Nakigozi, Thomas C. Quinn, Kate M. Grabowski,  
200 Larry W. Chang, Steven J. Reynolds, Tom Lutalo, Maria J. Wawer, Ronald H. Gray, Oliver  
201 Laeyendecker

## 202 **References**

- 203 1. Lescure, F.-X., et al., *Clinical and virological data of the first cases of COVID-19 in Europe: a case*  
204 *series*. The Lancet Infectious Diseases, 2020.
- 205 2. Johns Hopkins University, *JHU Corona Virus Resource Center*. 2020: Baltimore, MD 21218, United  
206 States.
- 207 3. Meyerowitz, E.A., et al., *Transmission of SARS-CoV-2: a review of viral, host, and environmental*  
208 *factors*. Annals of internal medicine, 2020.
- 209 4. Yanes-Lane, M., et al., *Proportion of asymptomatic infection among COVID-19 positive persons*  
210 *and their transmission potential: A systematic review and meta-analysis*. PloS one, 2020. **15**(11):  
211 p. e0241536.
- 212 5. Arons, M.M., et al., *Presymptomatic SARS-CoV-2 infections and transmission in a skilled nursing*  
213 *facility*. New England journal of medicine, 2020.
- 214 6. Nikolai, L.A., et al., *Asymptomatic SARS Coronavirus 2 infection: Invisible yet invincible*.  
215 International Journal of Infectious Diseases, 2020.
- 216 7. Furukawa, N.W., J.T. Brooks, and J. Sobel, *Evidence supporting transmission of severe acute*  
217 *respiratory syndrome coronavirus 2 while presymptomatic or asymptomatic*. Emerging infectious  
218 diseases, 2020. **26**(7).
- 219 8. B. Oketch., et al., *Health facilities run out of space as Covid-19 cases rise*, in *Daily Monitor*. 2020,  
220 Monitor Publications Limited: Kampala.
- 221 9. P. Ahimbisibwe., *Museveni orders two-week lockdown as COVID-19 cases rise*, in *Daily Monitor*.  
222 2020, Monitor Publications Limited: Kampala.
- 223 10. Ran, L., et al., *Risk factors of healthcare workers with corona virus disease 2019: a retrospective*  
224 *cohort study in a designated hospital of Wuhan in China*. Clinical Infectious Diseases, 2020.

- 225 11. Wang, X., et al., *Risk factors of SARS-CoV-2 infection in healthcare workers: a retrospective study*  
226 *of a nosocomial outbreak*. *Sleep Medicine: X*, 2020. **2**: p. 100028.
- 227 12. Papoutsis, E., et al., *Global burden of COVID-19 pandemic on healthcare workers*. 2020, Eur  
228 Respiratory Soc.
- 229 13. Twinamukye, P., *Uganda loses 58 doctors, nurses within one year*, in *Daily Monitor* 2021, Monitor  
230 Publications Limited Kampala.
- 231 14. Chang, L.W., et al., *Impact of a community health worker HIV treatment and prevention*  
232 *intervention in an HIV hotspot fishing community in Rakai, Uganda (mLAKE): study protocol for a*  
233 *randomized controlled trial*. *Trials*, 2017. **18**(1): p. 1-12.
- 234 15. Baker, O.R., et al., *Differential Performance of CoronaCHEK SARS-CoV-2 Lateral Flow Antibody*  
235 *Assay by Geographic Origin of Samples*. *Journal of Clinical Microbiology*, 2021: p. JCM. 00837-21.
- 236 16. Woodford, J., et al., *SARS-CoV-2 seroassay optimization and performance in a population with*  
237 *high background reactivity in Mali*. 2021.
- 238 17. Lapidus, S., et al., *Plasmodium infection induces cross-reactive antibodies to carbohydrate*  
239 *epitopes on the SARS-CoV-2 Spike protein*. medRxiv, 2021.
- 240 18. Grifoni, A., et al., *Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19*  
241 *disease and unexposed individuals*. *Cell*, 2020. **181**(7): p. 1489-1501. e15.
- 242 19. Choe, P.G., et al., *Waning Antibody Responses in Asymptomatic and Symptomatic SARS-CoV-2*  
243 *Infection*. *Emerg Infect Dis*, 2020. **27**.
- 244 20. Perreault, J., et al., *Waning of SARS-CoV-2 RBD antibodies in longitudinal convalescent plasma*  
245 *samples within 4 months after symptom onset*. *Blood, The Journal of the American Society of*  
246 *Hematology*, 2020. **136**(22): p. 2588-2591.

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261 **Table 1: Factors associated with SARS-CoV-2 seropositivity among Healthcare workers**

Sociodemographic characteristics		n (%) seropositive N=159	<u>Univariate</u>
			Odds Ratio (95% CI)
Sex	Male	61 (38.4)	0.9 (0.6-1.2)
	Female	98 (61.6)	Ref
Age category	15-24	33 (20.8)	0.7 (0.4- 1.1)
	25-34	57 (35.8)	Ref.
	35-44	39 (24.5)	0.8 (0.5-1.3)
	45-54	21 (13.2)	1.1 (0.6-1.9)
	55+	9 (5.7)	0.7 (0.3-1.5)
Cadre	Medical Officer	3 (1.9)	1.3 (0.4-5.1)
	Clinical Officer	8 (5.0)	1.8 (0.7-4.3)
	Nurse (all levels)	57 (35.8)	Ref
	Lab tech (all levels)	16 (10.1)	1.4 (0.8-2.7)
	Other staff	75 (47.2)	1.0 (0.7-1.5)

262

263

264 **Table 2: Factors associated with SARS-COV-2 seropositivity among phone-based survey**  
 265 **participants**

Sociodemographic characteristics		n (%) seropositive N=27	<u>Univariate</u>
			Odds Ratio (95% CI)
HIV status	Negative	14 (51.9)	Ref
	Positive	13 (48.1)	1.0 (0.5-2.3)
Sex	Male	9 (33.3)	0.9 (0.4-2.1)
	Female	18 (66.7)	Ref
Age category	15-24	0 (0.0)	
	25-34	7 (25.9)	0.9 (0.4. 2.4)

It is made available under a [CC-BY-NC-ND 4.0 International license](#) .

	35-44	14 (51.9)	Ref
	45-54	6 (22.2)	1.5 (0.5–4.2)
Occupation	Agriculture for home use/barter	10 (37.0)	Ref
	Agriculture for selling	1 (3.7)	0.1 (0.0-1.1)
	Fishing	3 (11.1)	1.2 (0.3-4.8)
	Shopkeeper	3 (11.1)	1.5 (0.4-6.7)
	Trading/vending	5 (18.5)	0.6 (0.2-2.0)
	Bar worker or owner	2 (7.4)	2.3 (0.4-14.3)
	Waitress/Waiter/restaurant owner	1 (3.7)	0.9 (1.0-8.8)
	Construction	1 (3.7)	4.6 (0.3-79.9)
	Boda Boda	1 (3.7)	1.5 (0.1-16.3)